Mitsubishi UFJ Trust & Banking Corp Reduces Stock Position in Abbott Laboratories $ABT

Posted by Stanley Muller on Aug 27th, 2026

Mitsubishi UFJ Trust & Banking Corp reduced its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 16.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 898,648 shares of the healthcare product maker’s stock after selling 181,956 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Abbott Laboratories were worth $81,543,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ABT. ANTIPODES PARTNERS Ltd acquired a new position in shares of Abbott Laboratories in the second quarter valued at approximately $67,000. Gold Investment Management Ltd. boosted its position in Abbott Laboratories by 12.2% during the second quarter. Gold Investment Management Ltd. now owns 11,886 shares of the healthcare product maker’s stock worth $1,079,000 after acquiring an additional 1,297 shares during the last quarter. Strata Wealth Advisors LLC purchased a new stake in Abbott Laboratories in the 2nd quarter worth approximately $287,000. Cane Capital Partners LLC purchased a new stake in Abbott Laboratories in the 2nd quarter worth approximately $276,000. Finally, Mechanics Financial Corp raised its holdings in Abbott Laboratories by 2.6% in the 2nd quarter. Mechanics Financial Corp now owns 8,619 shares of the healthcare product maker’s stock valued at $782,000 after acquiring an additional 217 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Trading Down 1.7%

Shares of ABT opened at $114.11 on Thursday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The firm has a market capitalization of $197.45 billion, a P/E ratio of 36.93, a price-to-earnings-growth ratio of 2.25 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock’s fifty day simple moving average is $101.66 and its 200 day simple moving average is $100.13.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first U.S. wearable designed to continuously monitor both glucose and ketone levels. The device is intended to help detect rising ketones associated with diabetic ketoacidosis and integrates with Abbott’s Libre app, digital-health ecosystem and compatible automated insulin-delivery systems. The approval strengthens Abbott’s continuous glucose-monitoring franchise and could expand its addressable market. Reuters FDA authorization article
Positive Sentiment: TD Cowen raised its price target for ABT from $115 to $135 and maintained a “buy” rating, implying approximately 18% upside from the referenced $114.11 level. The target increase reflects confidence in Abbott’s growth prospects and valuation relative to peers. Benzinga analyst price target report
Neutral Sentiment: Industry forecasts identify Abbott as a participant in expanding atrial-fibrillation treatment and device markets, particularly pulsed-field ablation, mapping catheters and left-atrial-appendage closure. These reports point to long-term opportunity but do not provide new Abbott-specific financial guidance. Atrial fibrillation treatment devices market report
Negative Sentiment: Abbott agreed to pay $670 million to settle claims that its specialized premature-infant formula contributed to necrotizing enterocolitis. The settlement removes some litigation uncertainty but highlights continuing legal and financial risks. Abbott formula claims settlement article

Analyst Upgrades and Downgrades

ABT has been the topic of several analyst reports. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. Citigroup increased their target price on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. JPMorgan Chase & Co. raised their price target on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. BTIG Research upped their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Finally, The Goldman Sachs Group decreased their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

Get Our Latest Analysis on ABT

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.